Full Text View
Tabular View
No Study Results Posted
Related Studies
Study Of An FDA-Approved Drug As Additional Therapy In Patients With Schizophrenia
This study has been completed.
Study NCT00086593   Information provided by GlaxoSmithKline
First Received: July 6, 2004   Last Updated: May 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
lamotrigine
Additional drug interventions recognized in this trial
Antipsychotic Agents
More general drug interventions related to this trial
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services